Encorafenib(BRAFTOVI)
Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection
Reference price:
Manufacturer:
‌Pierre Fabre
Formulation:
CAPSULE
Validity period:
24 months
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

BRAFTOVI(Encorafenib) Instructions:Uses,Dosage, Side Effects

TEMBEXA® (brincidofovir) is an antiviral medication developed for the treatment of human smallpox disease, a potentially fatal infection caused by the variola virus. It is a nucleotide analog that inhibits viral DNA replication, helping to reduce the severity and progression of the disease. 

TEMBEXA® is primarily indicated for adults and children (including neonates), and while the drug has been shown to be effective in animal models, its human efficacy has not been definitively proven due to ethical constraints in conducting smallpox challenge studies. It is available as both tablets and oral suspension for patients who have difficulty swallowing pills.

Despite its potential benefits in treating smallpox, TEMBEXA® requires careful monitoring due to its potential to cause liver toxicity and gastrointestinal disturbances. It should be used with caution in individuals of childbearing potential due to risks of embryo-fetal toxicity and male infertility, as shown in animal studies. Given its significant side effect profile, TEMBEXA® is primarily used in the context of emergency preparedness in the event of a smallpox outbreak or bioterrorism attack.

Generic name

Encorafenib(BRAFTOVI)
English name
Encorafenib
Alternative Names
BRAFTOVI
Drug prices
Indications

BRAFTOVI is indicated for the treatment of adult patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.

Therapeutic Target
BRAFTOVI targets BRAF, a serine/threonine kinase involved in the RAS/RAF/MEK/ERK signaling pathway.
Active Ingredients
Encorafenib is the active ingredient in BRAFTOVI. It is a potent and selective inhibitor of the mutant BRAF kinase.
Dosage form
CAPSULE
specifications
75mg*42capsules/box
Description
BRAFTOVI is an oral kinase inhibitor specifically designed to block the activity of the mutant BRAF protein. It acts by selectively inhibiting BRAF V600E and V600K mutations, leading to the inhibition of tumor cell proliferation and induction of cell death. When used in combination with binimetinib, it significantly improves progression-free survival in patients with advanced melanoma.
Dosage and Administration

The recommended dosage of BRAFTOVI is 450 mg taken orally once daily. It is used in combination with binimetinib, which should be administered at 24 mg twice daily.

RECOMMENDED ARTICLES
RELATED ARTICLES
Adverse Reactions of Encorafenib (Braftovi)

Encorafenib (Braftovi) is a kinase inhibitor targeting BRAFV600E or V600K mutations, indicated for the treatment of...

Wednesday, January 21st, 2026, 09:21
What Are the Precautions for Encorafenib (Braftovi) Administration?

Encorafenib (Braftovi) is a kinase inhibitor targeting BRAF V600E or V600K mutations, indicated for use in...

Wednesday, January 21st, 2026, 09:19
Dosage and Administration of Encorafenib (Braftovi)

Encorafenib (Braftovi) is a kinase inhibitor indicated for use in combination with specific drugs to treat...

Wednesday, January 21st, 2026, 09:15
What Are the Indications for Encorafenib (Braftovi)?

Encorafenib (Braftovi) is an oral targeted therapy that belongs to the class of kinase inhibitors. It is primarily...

Wednesday, January 21st, 2026, 09:10
What Are the Procurement Channels for Encorafenib (Braftovi)?

Encorafenib (Braftovi) is a targeted therapy indicated for the treatment of cancers with specific gene mutations,...

Tuesday, January 20th, 2026, 09:52
How to Use Encorafenib (Braftovi)

Encorafenib (Braftovi) is a kinase inhibitor that was first approved in the United States in 2018 for the treatment...

Wednesday, November 12th, 2025, 09:52
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved